Rich Insights into the Heart Failure Clinical Trial Analysis Featuring 75+ Companies and Therapies | DelveInsight

Currently, much research is ongoing to develop new and effective therapeutic drugs for the treatment of Heart failure. The treatment of HF is dependent on angiotensin-converting enzyme inhibitor, angiotensin receptor II blocker, beta-blockers, and diuretics. Additionally, other therapies, such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, nitrates, among others are used for the treatment of patients affected by heart failure. Biomarkers provide a low cost, low risk, and quick turnaround method to confirm or exclude a HF diagnosis, help to establish prognosis in the diagnosis, and more fundamentally, may provide substantial information on the complex pathophysiology that defines the syndrome of HF.

LAS VEGAS, April 4, 2023 /PRNewswire/ -- DelveInsight's 'Heart Failure Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline heart failure therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the heart failure pipeline domain.

Key Takeaways from the Heart Failure Pipeline Report

• DelveInsight's heart failure pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for heart failure treatment. 
• Key heart failure companies such as Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others are evaluating new heart failure drugs to improve the treatment landscape.
• Promising heart failure pipeline therapies in various stages of development include, Istaroxime, SERCA2a activators, hiPSC-derived cardiac cells, TRC 041266, TN-301, AAV-Based Research Project, DWORF, Qishenyiqi Dripping Pills, SG1002, Elamipretide, SQIN-01, TSG-01, Furoscix, SRD-001, SC 187, JK-07, Pirfenidone, HU6, RBM-003, RT 100, Relaxin-2, REGN5381, REC 02, Firibastat, Heart Failure Research Project, PROC-001, INXN-4001, Sildenafil citrate, APD-418, Prazosin hydrochloride, Pentosan Polysulfate Sodium (PPS), PL 3994, IPSC-derived cardiomyocyte, Dapansutrile, Semaglutide, MTC001, Rexlemestrocel-L (Revascor), Ertugliflozin, Sotagliflozin, Rivaroxaban, IONIS-AGT-LRx, IVS201, Lenrispodun, INL 1, IMB-101, IMR-687, Milrinone, Metolazone IV, HiCM-188, HS-001, Antisense oligonucleotide based therapy, GSK3884464, Research programme: heart failure therapeutics, iPSC-derived cardiac progenitor cells, IPSC-Based Tissue Therapy, Tirzepatide, LY3461767, EDG 002, DINA-007/A, DINA-007/B, Omecamtiv mecarbil, CK-136, IPSC-derived cell, CKD-349, CRD 733, Research programme: cardiovascular therapies, CRD-102, CDR132L, CardiolRx, Allogeneic Mesenchymal Bone Marrow Cells, Mavacamten, BMS-986231, FA relaxin, ROMK inhibitor, BR1016C, BR1016A, Research programme: induced pluripotent stem cell therapeutics, CardiAMP cell therapy, CardiALLO Cell Therapy, BC-007, Research programme: therapeutics, Finerenone (BAY 94-8862), Pecavaptan, MultiStem cell therapy, AZD4831, AZD 9977, AZD-8601, and others.
• In March 2023, Cardiol Therapeutics announced study results from one of its international collaborating research centers demonstrating that its pharmaceutically manufactured cannabidiol significantly prevents cardiac dysfunction and the development of fibrosis and cardiomyocyte hypertrophy in a pre-clinical model of heart failure and reduces expression of key inflammatory and fibrotic markers. 
• In March 2023, Sequana Medical announced positive results from its Phase 1 single-center, single-arm, single-dose trial (CHIHUAHUA) with its second-generation DSR product (DSR 2.0).
• In February 2022, Helsinn Group and AnaCardio were pleased to announce that AnaCardio had exercised its option to license from Helsinn a program in heart failure, a condition which is associated with poor quality of life, poor prognosis and which remains a major unmet medical need. 

Request a sample and discover the recent advances in heart failure drug treatment @ Heart Failure Pipeline Report

The heart failure pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage heart failure drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the heart failure clinical trial landscape.

Heart Failure Overview

Heart failure is a syndrome caused by structural and functional defects in the myocardium that impair ventricular filling or blood ejection. Reduced left ventricular myocardial function is the most common cause of heart failure. Increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate extracellular matrix proliferation, accelerated apoptosis, and genetic mutations are major pathogenic mechanisms leading to heart failure. Heart failure can significantly reduce a patient's functional capacity and increase the risk of death. Diagnosing and treating the disease effectively is critical to avoid recurrent hospitalizations, improve quality of life, and improve patient outcomes. 

Heart failure treatment necessitates a multifaceted approach that includes patient education, an optimal medical regimen to improve cardiac contractility, and the prevention/limitation of exacerbations. The primary heart failure symptoms are dyspnea and fatigue, which can limit exercise tolerance and lead to pulmonary and splanchnic congestion and peripheral edema. Heart failure is still a difficult problem and is now regarded as the most difficult challenge in cardiovascular medicine and surgery.

Find out more about drugs for heart failure @ New Heart Failure Drugs 

A snapshot of the Heart Failure Pipeline Drugs mentioned in the report:

Learn more about the emerging heart failure pipeline therapies @ Heart Failure Clinical Trials

Heart Failure Therapeutics Assessment

The heart failure pipeline report proffers an integral view of heart failure emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Heart Failure Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Therapeutics Assessment By Mechanism of Action: Gastric inhibitory polypeptide receptor agonists, Glucagon like peptide 1 receptor agonists, Mineralocorticoid receptor antagonists, Glutamyl aminopeptidase inhibitors, Metabolism stimulants, HDAC6 protein inhibitors, Cardiolipin modulators, Free radical scavengers, Mitochondrial permeability transition pore inhibitors, 
• Key Heart Failure Companies: Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others.
• Key Heart Failure Pipeline Therapies: Recombinant Human Neuregulin-1β (rhNRG-1), Istaroxime, SERCA2a activators, hiPSC-derived cardiac cells, TRC 041266, TN-301, AAV-Based Research Project, DWORF, Qishenyiqi Dripping Pills, SG1002, Elamipretide, SQIN-01, TSG-01, Furoscix, SRD-001, SC 187, JK-07, Pirfenidone, HU6, RBM-003, RT 100, Relaxin-2, REGN5381, REC 02, Firibastat, Heart Failure Research Project, PROC-001, INXN-4001, Sildenafil citrate, APD-418, Prazosin hydrochloride, Pentosan Polysulfate Sodium (PPS), PL 3994, IPSC-derived cardiomyocyte, Dapansutrile, Semaglutide, MTC001, Rexlemestrocel-L (Revascor), Ertugliflozin, Sotagliflozin, Rivaroxaban, IONIS-AGT-LRx, IVS201, Lenrispodun, INL 1, IMB-101, IMR-687, Milrinone, Metolazone IV, HiCM-188, HS-001, Antisense oligonucleotide based therapy, GSK3884464, Research programme: heart failure therapeutics, iPSC-derived cardiac progenitor cells, IPSC-Based Tissue Therapy, Tirzepatide, LY3461767, EDG 002, DINA-007/A, DINA-007/B, Omecamtiv mecarbil, CK-136, IPSC-derived cell, CKD-349, CRD 733, Research programme: cardiovascular therapies, CRD-102, CDR132L, CardiolRx, Allogeneic Mesenchymal Bone Marrow Cells, Mavacamten, BMS-986231, FA relaxin, ROMK inhibitor, BR1016C, BR1016A, Research programme: induced pluripotent stem cell therapeutics, CardiAMP cell therapy, CardiALLO Cell Therapy, BC-007, Research programme: therapeutics, Finerenone (BAY 94-8862), Pecavaptan, MultiStem cell therapy, AZD4831, AZD 9977, AZD-8601, and others.

Dive deep into rich insights for new drugs for heart failure treatment; visit @ Heart Failure Medications

Table of Contents

For further information on the heart failure pipeline therapeutics, reach out @ Heart Failure Drug Treatment

Related Reports

Heart Failure Market

Heart Failure Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key heart failure companies, including Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, among others.

Heart Failure Epidemiology Forecast

Heart Failure Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and heart failure epidemiology trends.

Advanced Heart Failure Pipeline

Advanced Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced heart failure companies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, among others.

Chronic Heart Failure Pipeline

Chronic Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic heart failure companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, among others.

Acute Heart Failure Pipeline

Acute Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute heart failure companies, including Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Blogs

Upcoming Cardiovascular Diseases Drugs

Key Companies in the Cardiology Segment

Heart Failure Market

Top Cardiac Devices in the Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us :
Shruti Thakur  
info@delveinsight.com  
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg